The company also carried out studies looking at the absorption of the orodispersible tablets and oral solution by the body.
Interaction with receptors other than dopamine and serotonin sub@@ types may explain some of the other clinical effects of ari@@ p@@ ipraz@@ o@@ le.
If a patient develops signs and symptoms indic@@ ative of N@@ MS, or presents with un@@ expl@@ ained high fever without additional clinical manife@@ stations of N@@ MS, all antipsychotic medicinal products, including ABILIF@@ Y@@ , must be discontinued.
Hyper@@ glycaemia and Di@@ ab@@ et@@ es M@@ ellit@@ us@@ : hyper@@ glycaem@@ ia, in some cases extreme and associated with ket@@ o@@ acidosis or hyper@@ os@@ mol@@ ar com@@ a or death, has been reported in patients treated with at@@ yp@@ ical antipsychotic agents, including ABILIF@@ Y@@ .
In clinical trials and post-marketing experienc@@ e, accidental or inten@@ tional acute over@@ dosage of ari@@ p@@ ipraz@@ ole alone was identified in adult patients with reported estimated doses up to 1,@@ 2@@ 60 mg with no fat@@ al@@ ities.
No studies on the effect on the ability to drive and use machines have been performed.
hyper@@ glycaem@@ ia, diabetes mellitus, diabetic ket@@ o@@ acidosis, diabetic hyper@@ os@@ mol@@ ar com@@ a
The overall comple@@ tion rate was significantly higher for patients on ari@@ p@@ ipraz@@ ole (4@@ 3%) than for hal@@ oper@@ id@@ ol (@@ 30@@ %).
Over@@ all, 1.@@ 3% of ari@@ p@@ ipraz@@ o@@ le-@@ treated patients reported cerebrovascular adverse events compared with 0.@@ 6% of placebo-treated patients in these trials.
4.@@ 7 Effects on ability to drive and use machines
Ac@@ tual scores in r@@ ating scal@@ es used as secondary end@@ point@@ s, including P@@ AN@@ SS and the Mont@@ g@@ omer@@ y-@@ As@@ berg De@@ pression R@@ ating Scale showed a significant improvement over hal@@ oper@@ id@@ ol.
15@@ 7 Tell your doctor immediately if you suffer from muscle stiff@@ ness or inf@@ lex@@ ibility with high fever, sweating, altered mental stat@@ us, or very rapid or irregular heart be@@ at.
ABILIFY may increase the effect of medicines used to lower the blood pressure.
The effects of Ab@@ ra@@ x@@ ane were first tested in experim@@ ental models before being studied in humans.
The reconstituted suspension should be milk@@ y and hom@@ ogenous without visible precipit@@ ates.
Moreover, monitoring of the blood pressure is recommended particularly at the start of therapy.
Treatment of adult patients scheduled for major elec@@ tive orthopaedic surg@@ ery@@ :
Ery@@ thro@@ po@@ ie@@ tin is a glycoprotein that stimul@@ ates, as a mit@@ os@@ is-@@ stimulating factor and differenti@@ ating hormon@@ e, the formation of erythro@@ cyt@@ es from precur@@ sors of the stem cell compart@@ ment.
In particular, no residues of the cell line used for the production are detectable at the concentrations of the active ingredient that are used in humans.
E@@ poetin alfa should be administered by the subcutaneous route to patients with anaemia (e. g. haemoglobin concentration ≤ 10 g/ dl (@@ 6.2 mmol/ l@@ ).
Star@@ ting dose of 50 IU/ kg 2 times per week by the intravenous rout@@ e.
A systematic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical trials.
N@@ on response to epoetin alfa therapy may have the following caus@@ es: ir@@ on, fol@@ ate, or vitamin B@@ 12 defici@@ ency@@ ; aluminium intoxic@@ ation; inter@@ current infection@@ s; inflammatory or traum@@ atic episod@@ es; oc@@ cul@@ t blood los@@ s; haem@@ olys@@ is, and bone marrow fibrosis of any origin.
Haem@@ oglobin vari@@ ability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/ dl (@@ 6.2 mmol/ l) to 12 g/ dl (7.5 mmol/ l@@ ).
Therefore, in patients with renal anaemia the medicinal product has to be administered intraven@@ ously.
Me@@ ta@@ -@@ analysis of overall survival data produced a hazard ratio point estimate of 1.0@@ 8 in favour of controls (95% CI:
Immuno@@ genicity data for subcutaneous use of Ab@@ se@@ am@@ ed in patients at risk for anti@@ bod@@ y-@@ induced PR@@ C@@ A, i. e. patients with renal anaemia, are not sufficient.
16@@ 8 MINI@@ MU@@ M PAR@@ TIC@@ UL@@ ARS TO AP@@ PE@@ AR ON B@@ LIST@@ ERS OR ST@@ RI@@ P@@ S
Therefore, if you are being treated for anaemia associated with kidney disease, Ab@@ se@@ am@@ ed has to be given by injection into a vein (@@ intraven@@ ous@@ ly).
Follow carefully all instructions given to you by your doctor or nur@@ se.
- The u@@ no@@ pen@@ ed bottle does not require any special storage conditions.
In one year clinical trials, pioglitazone consist@@ ently gave a statistically significant reduction in the album@@ in@@ / creatinine ratio compared to baseline.
• CON@@ DI@@ TIONS OR RE@@ ST@@ RI@@ C@@ TIONS WITH RE@@ G@@ AR@@ D TO THE SA@@ F@@ E AND EF@@ F@@ EC@@ TIVE USE OF THE MEDICINAL PRODUCT
- blurred vision due to swelling (or flu@@ id@@ ) in the back of the eye.
In@@ ten@@ si@@ fied control in the treatment of pregnant women with diabetes is therefore recommended throughout pregnancy and when cont@@ em@@ pl@@ ating pregnancy.
Close blood glucose monitoring is therefore recommended.
In patients with diabetes mellitus optim@@ ised glycaemic control delays the onset of late diabetic complications.
Usu@@ ally, the first symptoms of hyperglycaemia set in gradu@@ ally, over a period of hours or days.
Insulin hum@@ an, r@@ DNA (@@ produced by recombinant DNA technology in S@@ acchar@@ omyc@@ es cere@@ vis@@ ia@@ e).
When turning the dose selec@@ tor be careful not to push the push@@ - button as insulin will come out.
This process is influ@@ enced by several factors (e. g. insulin dos@@ age, injection route and site, thick@@ ness of subcutaneous fat, type of diabet@@ es).
Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
Patients whose blood glucose control is greatly improved e. g. by intensi@@ fied insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.
EX@@ P@@ / During us@@ e: use within 6 weeks
Tal@@ k about your insulin needs with your doctor and diabetes nur@@ se.
Vit@@ amin D@@ 3, along with other forms of vitamin D, is required for calcium absorption and normal bone form@@ ation.
Oste@@ on@@ ec@@ rosis of the ja@@ w, generally associated with tooth extrac@@ tion and/ or local infection (including oste@@ omyel@@ itis) has been reported in patients with cancer who are receiving treatment regim@@ ens including primarily intraven@@ ously administered bisphosphon@@ ates.
4.@@ 7 Effects on ability to drive and use machines
Tal@@ k to your doctor first and follow the advice given.
ADROVANCE 70 mg/ 2800 IU tablets are available as capsu@@ le-@@ shap@@ ed, white to off-white tablets marked with an out@@ line of a bone image on one side and ‘ 7@@ 10 '@@ on the other.
A double dose should not be taken on the next morning.
per@@ ic@@ ardi@@ al eff@@ usion ech@@ ocardi@@ og@@ ram abnormal
In rats, female reproductive function including birth was impaired at toxic doses and the offspring showed reduced birth weigh@@ ts, vi@@ ability and growth.
Met@@ abolic interactions System@@ ically available tacrolimus is metabolised by hepatic CYP3A@@ 4.
The formation of neutr@@ alising antibodies (@@ inhibitors) against factor VIII is a known complic@@ ation in the management of individuals with haemophilia A.
More extensive haemarthro@@ sis, muscle bleeding or haemat@@ om@@ a.
In case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (@@ in@@ % of normal or IU/ d@@ l) in the corresponding period.
4.4 Special warnings and precautions for use
Re@@ qu@@ ired units (@@ IU) = body weight (@@ kg) x desired factor VIII rise (%) x 0.5
Haem@@ at@@ oc@@ rit decreased Laboratory test abnormal Injury, poisoning and Post procedural procedural complications complic@@ ation
W@@ ash your hands thoroughly using so@@ ap and war@@ m water.
- if you are allergic (hypersensitive) to oc@@ toc@@ og alfa or any of the other ingredients of AD@@ V@@ ATE
If any of these symptoms occur, stop the injection immediately and contact your doctor.
After reconstitution the solution should be clear, colourless and free from foreign particles.
Symptoms of overdose are mostly of a sympathomime@@ tic nature.
You may need to read it again.
Agener@@ ase boost@@ ed with low-@@ dose ritonavir has been compared with other protease inhibitors in 20@@ 6 adults who had taken protease inhibitors in the past.
No dose adjustment for either medicinal product is necessary when zidovudine is administered in combination with ampren@@ avir.
Agener@@ ase is not recommended for use as mono@@ therapy, due to the rapid emergence of resistant virus.
- if you have severe liver disease (see ‘ Take special care with Agener@@ as@@ e@@ ’).
- If you have had liver disease discuss this with your doctor.
Ask your doctor or pharmacist before taking any medicine.
Marketing Authorisation Holder and Manufacturer
Application site bleeding Application site pap@@ ules Application site par@@ aesthesia
In those im@@ iqu@@ im@@ od patients who achieved total clearance of their war@@ ts, the median time to clearance was 12 weeks.
This Regi@@ stry will collect long-term safety and efficacy data in patients treated with Aldurazyme as well as data on the natural progression of the disease in patients not on treatment.
Dosage The recommended dosage regimen of Aldurazyme is 100 U/ kg body weight given once every week as an intravenous infusion.
If you experience any reaction like this, please tell your doctor immediately.
Do not use Aldurazyme after the expiry date which is stated on the label after the letters EX@@ P.
No dose reductions other than those recommended for all patients are necessary.
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (P@@ SUR@@ ).
L@@ osing around 0.5 kg (1 l@@ b) per week is ide@@ al.
EU/ 1/ 02@@ / 22@@ 4/ 001 1 pre-filled syringe without needle EU/ 1/ 02@@ / 22@@ 4/ 002 1 pre-filled syringe with needle EU/ 1/ 02@@ / 22@@ 4/ 003 10 pre-filled syringes without needles EU/ 1/ 02@@ / 22@@ 4/ 004 10 pre-filled syringes with needles EU/ 1/ 02@@ / 22@@ 4/ 005 50 pre-filled syringes without needles
You may need to read it again.
Sol@@ u@@ tions containing particul@@ ate matter should not be used.
Each ml contains 100 Un@@ its insulin gl@@ ul@@ is@@ ine (@@ equivalent to 3.@@ 49 mg).
Non-@@ clinical data did not reveal toxicity findings others than those linked to the blood glucose lowering pharmacodynamic activity (@@ hypo@@ glyc@@ em@@ ia), different from regular human insulin or of clinical relevance for humans.
Air bubbles must be removed from the cartridge before injection (see instruc@@ tion for using pen@@ ).
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Ap@@ id@@ ra can be injected in the abdominal w@@ all, the thigh or upper arm or by continuous infusion in the abdominal w@@ all.
- Do not take a double dose to make up for a forgotten dose.
One mill@@ ilit@@ re of the solution contains 100 Un@@ its of the
- you have just begun insulin treatment or changed to another insulin prepar@@ ation,
you have an injury, operation, infection or fever,
In such a case, you may develop severe hypoglycaemia (and even@@ fain@@ t) before you are aware of the problem.
The combination should be administered with cau@@ tion, especially in the elder@@ ly.
Irbesartan and its metabolites are eliminated by both biliary and renal path@@ ways.
Ad@@ j@@ ust@@ ed mean change of trough se@@ ated di@@ ast@@ olic blood pressure (S@@ e@@ D@@ B@@ P) was as follows:
When the individual components of the primary endpoint were analy@@ sed, no effect in all cause mortality was observ@@ ed, while a positive trend in the reduction in ES@@ R@@ D and a significant reduction in dou@@ bling of serum creatinine were observed.
EU/ 1/ 97/ 046/ 021 14 tablets EU/ 1/ 97/ 046/ 022 28 tablets EU/ 1/ 97/ 046/ 0@@ 35 30 tablets EU/ 1/ 97/ 046/ 023 56 tablets EU/ 1/ 97/ 046/ 024 56 x 1 tablets EU/ 1/ 97/ 046/ 0@@ 32 84 tablets EU/ 1/ 97/ 046/ 0@@ 38 90 tablets EU/ 1/ 97/ 046/ 025 98 tablets
If you take certain pain@@ kill@@ ers, called non-@@ steroid@@ al anti-@@ inflammatory drugs, the effect of irbesartan may be reduced.
Driving and using machines No studies on the effects on the ability to drive and use machines have been performed.
Her@@ bal preparations containing St John's wort (@@ Hypericum perforat@@ um) must not be used while taking AP@@ TIV@@ US due to the risk of decreased plasma concentrations and reduced clinical effects of tipran@@ avir (see section 4.5).
The@@ ophy@@ l@@ line plasma concentrations should be monitored during the first two weeks of co@@ - administration with AP@@ TIV@@ US@@ / ritonavir and the the@@ ophy@@ l@@ line dose should be increased as needed.
Response rates were higher in AP@@ TIV@@ US@@ / ritonavir patients than comparator P@@ I boost@@ ed with ritonavir in new enfuvir@@ tide patients, or patients without new enfuvir@@ ti@@ de.
P@@ ure red cell ap@@ las@@ ia caused by neutr@@ alising anti-@@ erythropoietin antibodies has been reported in association with recombinant erythropoie@@ tic proteins, including darbepoetin alfa.
C@@ lear@@ ance of darbepoetin alfa is 1.@@ 9 ml/ hr@@ / kg (S@@ D 0.5@@ 6) and the volume of distribution (V@@ s@@ s) is approximately equal to plasma volume (50 ml/ kg@@ ).
No guidance regarding the correc@@ tion of haemoglobin is available for paediatric patients 1 to 10 years of age.
P@@ ure red cell ap@@ las@@ ia caused by neutr@@ alising anti-@@ erythropoietin antibodies has been reported in association with recombinant erythropoie@@ tic proteins, including darbepoetin alfa.
Adverse events at very high doses were all considered to be related to an exagg@@ erated pharmacological
If after a dose reduction, haemoglobin continues to increase, the dose should be tempor@@ arily with@@ held until the haemoglobin beg@@ ins to decreas@@ e, at which point therapy should be re@@ initiated at approximately 25% lower than the previous dose.
A re@@ tic@@ u@@ loc@@ y@@ te count should be considered as part of the evalu@@ ation.
Pharmacokinetic parameters did not change on multiple dosing over 12 weeks (@@ dosing every week or every two week@@ s).
Treatment of symptomatic anaemia in adult cancer patients with non-@@ myel@@ oid malignancies receiving chemotherapy.
In patients not on di@@ alysis, once the target haemoglobin has been achieved with once every two week dos@@ ing, Aranesp may be administered subcutaneously once monthly using an initial dose equal to twice the previous once every two week dose.
In the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.@@ 47 in favour of controls.
Guid@@ ance is given separ@@ ately for adult and paediatric patients.
In a prospec@@ tive, randomised double-@@ blin@@ d, placebo-controlled study conducted in 34@@ 4 anaem@@ ic patients with lymph@@ oproliferative malignancies receiving chemotherapy there was a significant reduction in transf@@ usion requirements and an improvement in haemoglobin response (p < 0.00@@ 1).
These antibodies have been shown to cross-@@ react with all erythropoie@@ tic proteins, and patients suspected or confirmed to have neutr@@ alising antibodies to erythropoietin should not be switched to darbepoetin alfa (see section 4.8).
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythro@@ id progenitor cells in the bone marrow.
Dosing should be titrated as necessary to maintain the haemoglobin targ@@ et.
C@@ lear@@ ance of darbepoetin alfa is 1.@@ 9 ml/ hr@@ / kg (S@@ D 0.5@@ 6) and the volume of distribution (V@@ s@@ s) is approximately equal to plasma volume (50 ml/ kg@@ ).
In the chronic toxicity studies no tum@@ ou@@ ri@@ genic or un@@ expected mit@@ ogenic responses were observed in any tissue type@@ .
Sub@@ cutaneous use is prefer@@ able in patients who are not receiving haemodialysis to avoid the punc@@ ture of peripheral ve@@ ins.
Pharmacokinetic parameters did not change on multiple dosing over 12 weeks (@@ dosing every week or every two week@@ s).
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Very common (≥ 1/ 10@@ ); common (≥ 1/ 100 to < 1/ 10@@ ); uncommon (≥ 1/ 1,000 to < 1/ 100@@ ); rare (≥ 1/ 10,000 to < 1/ 1,000@@ ); very rare (< 1/ 10@@ ,@@ 000@@ ), not known (@@ cannot be estimated from the available dat@@ a).
Co@@ le@@ st@@ yr@@ amine given orally at a dose of 8 g three times a day for 24 hours to three healthy volunteers decreased plasma levels of A@@ 77@@ 17@@ 26 by approximately 40% in 24 hours and by 4@@ 9% to 6@@ 5% in 48 hours.
Patients may be started on le@@ fl@@ un@@ om@@ ide 10 mg or 20 mg depending on the severity (@@ activ@@ ity) of the disease. • The recommended maintenance dose is 20 mg once daily for patients with psoriatic arthritis (see section 5.1).
The effect of le@@ fl@@ un@@ om@@ ide on improvement of function and on reduction of skin lesions was mo@@ dest@@ .
A complete wash@@ out is essential in such cases.
- if you experience weakness, feel light-@@ head@@ ed or dizz@@ y or have difficulty breathing, as these
The underlying mechanism and the clinical relevance are unknown.
R@@ ash Swe@@ ating increased N@@ ight swe@@ ats
Ser@@ ot@@ onin syndrome@@ : you should tell your doctor if you are taking any of the medicines that act in a similar way to dulox@@ et@@ ine.
Taking A@@ RI@@ CL@@ AI@@ M with food and drink A@@ RI@@ CL@@ AI@@ M may be taken with or without food.
4.@@ 7 Effects on ability to drive and use machines
Hepatic impairment - Following a sing@@ le, subcutaneous dose of fondaparinux in subjects with moderate hepatic impairment (@@ Child-Pugh Category B@@ ), total (i. e., bound and un@@ b@@ ound@@ ) Cmax and AUC were decreased by 22% and 39@@ %, respectively, as compared to subjects with normal liver function.
EU/ 1/ 02@@ / 20@@ 6/ 027 - 2 pre-filled syringes with a manual safety system EU/ 1/ 02@@ / 20@@ 6/ 028 - 10 pre-filled syringes with a manual safety system EU/ 1/ 02@@ / 20@@ 6/ 0@@ 33 - 20 pre-filled syringes with a manual safety system
Ari@@ x@@ tra is a medicine that helps prevent blood clots from form@@ ing in the blood vessels (@@ an anti@@ thrombotic ag@@ ent@@ ).
85 If you forget to take Ari@@ x@@ tra • Take the dose as soon as you rememb@@ er.
Caution is also needed when Atripla is taken at the same time as other medicines.
Atripla must not be used in patients with severe hepatic impairment (C@@ PT Gr@@ ade C) (see section 5.2).
Laboratory tests should be performed to evaluate their liver disease at periodic intervals (see section 4.2).
two weeks (@@ until stable concentrations are reach@@ ed) is recommended when starting or stopping treatment with Atripl@@ a.
Diffe@@ rence between Atripla and original treatment regimen
Any unused product or waste material should be disposed of in accordance with local requirements.
In view of the potential for development of heart failure in these patients, rosiglitazone should therefore not be initiated in patients having an acute coronary event and it should be discontinued during the acute phase (see section 4.3).
CON@@ DI@@ TIONS OF THE MARKETING AUTHORISATION
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Urinary excretion accoun@@ ted for approximately 1% and 2% of the orally and intraven@@ ously administered dose, respectively.
General disorders and administration site conditions oedema
Hypo@@ glycaemia Patients receiving A@@ VAN@@ D@@ A@@ ME@@ T in combination with a sulphonylurea or insulin may be at risk for dose-@@ related hypoglycaem@@ ia.
23 Adverse reactions for each treatment regimen are presented below by system organ class and absolute frequ@@ ency.
Read the package leaflet before use.
The Committee recommended that Av@@ an@@ di@@ a be given marketing author@@ isation.
Skin and subcutaneous tissue disorders (see Immun@@ e system disorder@@ s) angi@@ oedema skin reactions (e. g. urtic@@ aria, pruritus, rash) 5
Insulin should only be added to established rosiglitazone therapy in exceptional cases and under close supervision.
as monotherapy – in patients (particularly overweight patients) in@@ adequately controlled by diet and exercise for whom metformin is inappropriate because of contraindic@@ ations or intolerance
The long-term benefits of therapy with rosiglitazone have not been demonstrated (see section 5.1).
Avonex is used to treat the following group@@ s: • patients with relap@@ sing multiple sclerosis (M@@ S).
This leaflet was last approved in {MM@@ /@@ YYYY}
Ma@@ ke sure the cap is int@@ act and has not been open@@ ed.
A@@ x@@ ura has been studied in three main studies including a total of 1,@@ 1@@ 25 patients with Alzheimer's disease, some of whom had taken other medicines for their disease in the past.
Cardiac disorders
Ask your pharmacist how to dispose of medicines no longer required.
- If you take a large overdose of A@@ x@@ ur@@ a, contact your doctor or get medical adv@@ ice, as you may
AZ@@ AR@@ GA is a combination of treatments for gl@@ au@@ com@@ a.
Caution should be used when initi@@ ating treatment with ras@@ ag@@ il@@ ine in patients with mild hepatic insufficiency.
Each tablet contains 1 mg of ras@@ ag@@ il@@ ine (as mes@@ il@@ ate@@ ).
Az@@ omy@@ r tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psych@@ om@@ otor performance in clinical trials.
In addition to the established classi@@ fications of seas@@ on@@ al and pe@@ ren@@ ni@@ al, allergic rh@@ initis can altern@@ atively be classified as inter@@ mit@@ tent allergic rh@@ initis and persistent allergic rh@@ initis according to the duration of symptoms.
Treatment with Az@@ omy@@ r also significantly reduced inter@@ ference with sleep and day@@ time function, as measured by a four@@ -@@ point scale used to assess these vari@@ ab@@ les.
NAME OF THE MARKETING AUTHORISATION HOLDER
If you are pregnant or nursing a baby, taking Az@@ omy@@ r syrup is not recommended.
This observation is based on limited experience in 45 patients with Child-Pugh score ≥ 7 at the start of entecavir treatment.
Am@@ ylase levels > 3 times baseline occurred in 2% of patients, lip@@ ase levels > 3 times baseline in 18@@ % and platelets < 50@@ ,@@ 000@@ / mm@@ 3 in < 1@@ %.
M@@ echan@@ ism of ac@@ tion: entec@@ avir, a gu@@ anosine nucleoside analogue with activity against HBV polymer@@ ase, is effici@@ ently phosphor@@ ylated to the active tri@@ phosphate (T@@ P) form, which has an intracellular half-life of 15 hours.
There are insufficient data to provide information on inhibitor incidence in P@@ U@@ P@@ s.
It has a primary amino acid sequ@@ ence that is comparable to the Al@@ a@@ 14@@ 8 all@@ el@@ ic form of plasma-derived factor IX@@ , and some post-@@ transl@@ ational modifications of the recombinant molecule are different from those of the plasma-derived molecu@@ le.
Chem@@ ical and physical in-@@ use st@@ ability has been demonstrated for 3 hours at temperatures up to 25@@ o@@ C.
BeneFIX is a coagulation factor IX product that is produced by recombinant technology.
A dose of either 3 mg (@@ if the affected limb is your arm@@ ) or 4 mg (@@ if the affected limb is your leg@@ ) of BE@@ RO@@ M@@ UN will be administered by IL@@ P for an initial period of 30 minutes.
This product contains human albumin and hence carries a potential risk for transmission of viral diseases.
If reactions are severe, Betaferon should be discontinued and appropriate medical intervention in@@ stit@@ uted.
This treatment effect was still evident after the additional year of follow-up at which stage the risk reduction was 41% (H@@ az@@ ard R@@ atio = 0.5@@ 9, 95% confidence interval (0.@@ 4@@ 2, 0.8@@ 3), p = 0.00@@ 1@@ 1). Within the study period of three years, CD@@ MS occurred in 5@@ 1% of the delayed treatment group compared to 37@@ % of the immediate treatment group (@@ Kaplan-Meier estim@@ at@@ es).
*@@ Betaferon is formul@@ ated to contain a calculated over@@ fill of 20@@ %.
It is not known whether Interferon beta-1@@ b passes into human breast milk.
One way to do that is to note the injection site on the enclosed medication record card.
Hyper@@ ten@@ sion may occur in epoetin alfa treated patients.
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron defici@@ ent.
Di@@ alysis prescrip@@ tions may have to be adjusted periodically to maintain ure@@ a, creatinine and potassium in the desired range.
50 IU/ kg 3 times per week by the intravenous rout@@ e.
An@@ aemia symptoms and sequ@@ el@@ ae may vary with age, gender, and overall burden of diseas@@ e; a physici@@ an@@ ´s evaluation of the individual patient@@ ´s clinical course and condition is necessary.
50 IU/ kg 3 times per week by the intravenous rout@@ e.
In controlled clinical studies, use of E@@ poetin alfa and other erythropoies@@ is-@@ stimulating agents (E@@ SA@@ s) have sho@@ wn@@ :
A systematic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical trials.
Altern@@ atively, the injection can be given at the end of the dialysis session via the fist@@ ula needle tub@@ ing, followed by 10 ml of isot@@ onic saline to rinse the tubing and ensure satisfactory injection of the product into the circul@@ ation.
B@@ in@@ oc@@ rit 2000 IU/ 1 ml solution for injection in a pre-filled syringe The syringes contain 1 ml (@@ 2000 IU) of solution.
Head@@ ach@@ e and diarrhoea have been reported shor@@ tly after starting filgrastim therapy, typically in less than 10% of patients.
Use of filgrastim@@ , either alone or after chemotherapy, mobil@@ ises haemat@@ opo@@ ie@@ tic progenitor cells into peripheral blood.
32 PAR@@ TIC@@ UL@@ ARS TO AP@@ PE@@ AR ON THE O@@ UTE@@ R PAC@@ K@@ AG@@ ING
Bond@@ enza 3 mg solution for injection I@@ band@@ ronic acid For IV use only
If you inadver@@ t@@ ently inject into the tissues around the ve@@ in, patients may experience local irritation, pain and inflammation at the injection site.
The pain reduction was consist@@ ently below baseline throughout the entire study and accompanied by a significantly reduced use of analges@@ ics.
No evidence of direct foetal toxicity or teratogenic effects were observed for ib@@ and@@ ronic acid in intraven@@ ously treated rats and rab@@ bit@@ s.
You may need to read it again.
If you are under dental treatment or will undergo dental surger@@ y, tell your d@@ enti@@ st that you are being treated with Bon@@ dr@@ on@@ at.
- not enough c al@@ cium and vitamin D in the diet
Interactions due to the lasting effect of rocuronium or vec@@ uron@@ i@@ um@@ :
This leaflet was last approved in {MM/ YYYY}
The mal@@ form@@ ations included serious heart and/ or major vessels anomal@@ i@@ es: a common tr@@ unc@@ us arter@@ i@@ osis and no duct@@ us arter@@ i@@ osis, co@@ arc@@ tation of the pulmonary tr@@ un@@ k and the pulmonary arter@@ ies, intrav@@ ent@@ ric@@ ular defects of the hear@@ t.
Instructions for use Pri@@ or to and following each infus@@ ion, fl@@ ush the ind@@ w@@ elling ca@@ the@@ ter line with approximately 5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection or glucose (5@@ %) solution for injection.
Read this gu@@ ide prior to the preparation and administration of Bus@@ il@@ v@@ ex.
• The diluted solution must be mixed thoroughly by inver@@ ting several times
The effect of BYETTA to slow gastric emp@@ ty@@ ing may reduce the extent and rate of absorption of orally administered medicinal products.
- As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac
Like all medicines, Ca@@ el@@ y@@ x can cause side effects, although not every@@ body gets them.
C@@ AN@@ CI@@ D@@ AS 70 mg powder for concentrate for solution for infusion Cas@@ po@@ fung@@ in (as acet@@ ate)
BEFORE YOU TAKE C@@ AN@@ CI@@ D@@ AS
Bre@@ ast@@ -fe@@ eding during the use of car@@ gl@@ um@@ ic acid is contraindicated (see sections 4.6 and 5.3).
For heart transpl@@ ants, the recommended adult dose is 1.5 g twice a day by mouth, starting within five days following the transpl@@ ant.
In terat@@ ology studies in rats and rab@@ bit@@ s, foetal res@@ or@@ p@@ tions and mal@@ form@@ ations occurred in rats at 6 mg@@ • kg@@ -1@@ • day@@ -1 (including an@@ ophthalm@@ ia, ag@@ n@@ ath@@ ia, and hydro@@ ce@@ ph@@ aly@@ ) and in rab@@ b@@ its at 90 mg@@ • kg@@ 1@@ • day@@ -1 (including cardiovascular and renal anomal@@ ies, such as ec@@ top@@ ia cor@@ dis and ec@@ topic kidne@@ ys, and di@@ aph@@ r@@ ag@@ m@@ atic and um@@ bil@@ ical her@@ n@@ ia), in the absence of maternal toxicity.
Mycophenolate mofetil has been shown to be excreted in the milk of lact@@ ating rats.
Median peak maraviroc plasma concentrations is at@@ tained at 2 hours (range 0.@@ 5-@@ 4 hour@@ s) following single oral doses of 300 mg commercial tablet administered to healthy volunteers.
In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (C@@ AR@@ T@@ ), an inflammatory reaction to asymptom@@ atic or residual opportun@@ istic infections may arise (see section 4.4).
P@@ ou@@ et de Cam@@ il@@ o, 2 E@@ - 46@@ 39@@ 4 Rib@@ ar@@ ro@@ ja del T@@ uria (@@ Val@@ enc@@ ia) Tel: + 34 96 27@@ 2@@ 2800
Some of them must not be taken during treatment with Ceplene or may need special precau@@ tion@@ s: • S@@ ter@@ oid@@ s such as pre@@ dn@@ is@@ one and dexameth@@ as@@ one.
If you are using a syringe pump you must refer to the instructions provided by the pump manufacturer and the training provided by your doctor, nurse and/ or pharmacist.
The measurement of protein C activity using chro@@ m@@ ogenic substr@@ ates is recommended for the determination of your plasma level for protein C before and during treatment with CEPRO@@ TIN@@ .
Patients who have developed antibodies or symptoms of hypersensitivity to Cere@@ d@@ ase (@@ al@@ gluc@@ er@@ as@@ e) should be treated with caution when administering Cere@@ z@@ yme (@@ im@@ ig@@ luc@@ er@@ as@@ e).
Any unused product or waste material should be disposed of in accordance with local requirements.
Po@@ w@@ der@@ : vial (@@ gl@@ ass@@ ) Sol@@ vent@@ : pre-filled syringe (@@ gl@@ ass@@ )
Do not use if the solution contains particles or if the solution is not clear@@ .
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
50 PAR@@ TIC@@ UL@@ ARS TO AP@@ PE@@ AR ON THE O@@ UTE@@ R PAC@@ K@@ AG@@ ING
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
Col@@ es@@ ev@@ el@@ am is a non-@@ absor@@ be@@ d, lip@@ id@@ -@@ lowering poly@@ mer that binds b@@ ile acids in the intest@@ ine, imp@@ eding their re@@ absor@@ p@@ tion.
7 High density polyethylene bottles with a poly@@ propylene cap without outer carton.
Cholestag@@ el tablets are off-@@ white, capsu@@ le-@@ shaped film-coated tablets and im@@ printed with ‘ Cholestag@@ el@@ '@@ on one side.
The co-@@ administration of dox@@ azosin (4 and 8 mg dail@@ y) and t@@ adalafil (5 mg daily dose and 20 mg as a single dose) increases the blood pressu@@ re-@@ lowering effect of this alpha@@ -@@ blocker in a significant manner.
Ch@@ ec@@ k carefully how you react to the medicines before driving or using any machin@@ er@@ y.
In view of the lack of data, clo@@ p@@ idogrel cannot be recommended during the first 7 days after acute ischaem@@ ic stro@@ ke.
Co@@ Aprovel is not indicated in patients with severe hepatic impairment.
There were no toxic@@ ological findings observed of relevance to human therapeutic use.
WHAT CO@@ A@@ PRO@@ VE@@ L IS AND WHAT IT IS USED FOR
Always take Co@@ Aprovel exactly as your doctor has told you.
Val@@ pro@@ ic acid, flu@@ con@@ azole or methadone when co-administered with zidovudine have been shown to increase the AUC of zidovud@@ ine, with a corresponding decrease in its clear@@ ance.
The antihypertensive effect persi@@ sts over 24 hours after administration.
In two long-term follow-up studies the effect of Copalia was maintained for over one year.
Copalia 5 mg/ 160 mg film-coated tablets amlodip@@ ine/ valsartan
Copalia is available in packs containing 7, 14@@ , 28@@ , 30, 5@@ 6, 90@@ , 98 or 28@@ 0 tablets and in multi@@ packs comprising 4 car@@ ton@@ s, each containing 70 tablets.
30 MINI@@ MU@@ M PAR@@ TIC@@ UL@@ ARS TO AP@@ PE@@ AR ON B@@ LIST@@ ERS OR ST@@ RI@@ P@@ S
- if you suffer from moderate liver problems,
It is available as white capsules (@@ 100@@ , 200@@ , 3@@ 33 and 400 mg).
Clinical examination should include evaluation for physical signs of fat re@@ distribution.
Anti@@ retroviral activity was un@@ altered when didanosine was administered 3 hours after treatment with indin@@ avir.
Sa@@ quin@@ avir 600 mg S@@ D (@@ hard gel capsule formul@@ ation) (@@ Indinavir 800 mg TI@@ D)
Keep the bottle tigh@@ tly closed in order to protect from moist@@ ure.
If you stop taking CRIXIV@@ AN It is important that you take CRIXIV@@ AN exactly as your doctor prescrib@@ es.
The Committee recommended that Cub@@ icin be given marketing author@@ isation.
DATE OF FIRST AUTHORISATION@@ / RENEWAL OF THE AUTHORISATION
(44-20) 74 18 84 00 F@@ ax (44-20) 74 18 84 16 E-mail: mail@@ @@@ emea. europa. eu http: / /www. emea. europa. eu ©@@ EMEA 2007 Re@@ production and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged hospital with suspected cyanide poisoning and who received Cyanok@@ it.
Symptoms of brain damage resolved in 38 of 66 patients.
Cyanok@@ it does not substitute oxygen therapy and must not delay the set up of the above measures.
Subsequ@@ ently, the physician may continue decreasing the dose, but at a more gradual rate.
The pat@@ ter@@ n of liver damage was predominantly hepat@@ oc@@ ellul@@ ar.
CY@@ MB@@ ALTA showed comparable efficacy results to venlafaxine in terms of improvements on the HA@@ M@@ -@@ A total sco@@ re.
The Committee for Medicinal Products for Human Use (CHMP) decided that D@@ af@@ iro@@ 's benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on amlodipine or valsartan mono@@ therapy.
One blister contains 7, 10 or 14 film-coated tablets.
Ste@@ ad@@ y-@@ state plasma levels are reached after continuous administration for 7@@ – 8 days.
Pregnancy An@@ gi@@ ot@@ ensin II Rec@@ ept@@ or Ant@@ agon@@ ists (A@@ II@@ RA@@ s) should not be initiated during pregnancy.
SPECIAL W@@ AR@@ N@@ ING T@@ HAT THE MEDICINAL PRODUCT MU@@ ST B@@ E ST@@ O@@ RE@@ D O@@ U@@ T OF THE REACH AND SI@@ G@@ H@@ T OF C@@ HI@@ LD@@ RE@@ N
Medicines should not be disposed of via wastewater or household waste.
In the majority of patients such treatment will be part of symptomatic pal@@ li@@ ation of the disease.
Tell the medical staff@@ , who will be monitoring you during this time, if you suffer fro@@ m@@ :
It must not be used in patients who have had psych@@ os@@ es (a serious mental state with a distor@@ ted sense of re@@ al@@ ity) with attacks of deli@@ ri@@ um (a mental state with confusion, exc@@ it@@ ement, rest@@ lessness and hallucin@@ ation@@ s).
The following pharmacokinetic properties of sti@@ rip@@ ent@@ ol have been reported from studies in adult healthy volunteers and adult patients.
Un@@ desirable combinations (to be avoided unless strictly necessar@@ y)
Increased risk of dose-@@ dependent adverse reactions such as rhabdomyolys@@ is (@@ decreased hepatic metabolism of cholesterol@@ -@@ lowering ag@@ ent@@ )
5.@@ 3 Pre@@ clinical safety data Tox@@ icity studies in animals (r@@ at, mon@@ ke@@ y, mou@@ se@@ ) have not revealed any consistent pat@@ ter@@ n of toxicity apart from liver enlargement associated with hepat@@ oc@@ ellular hyper@@ troph@@ y, which occurred when high doses of sti@@ rip@@ ent@@ ol were administered to both rodents and non@@ rod@@ ents.
In the pivotal studies, when the use of Diacomit was initi@@ ated, the daily dose of c@@ lob@@ az@@ am was 0.5 mg/ kg/ day usually administered in divided doses, twice daily.
S@@ ti@@ rip@@ ent@@ ol enh@@ ances the central depres@@ sant effect of chlor@@ pro@@ ma@@ z@@ ine.
• In@@ duc@@ tion chemotherapy followed by radio@@ therapy (@@ TA@@ X@@ 32@@ 3) The safety and efficacy of docetaxel in the induction treatment of patients with squ@@ am@@ ous cell carc@@ in@@ oma of the head and neck (S@@ C@@ CH@@ N@@ ) was evaluated in a phase II@@ I, mul@@ tic@@ ent@@ er, open-@@ lab@@ el, randomized trial (@@ TA@@ X@@ 32@@ 3).
A H@@ az@@ ard ratio of less than 1 fav@@ ors docetaxel + cisplatin + 5-@@ F@@ U *@@ Co@@ x model (@@ adjustment for Prim@@ ary tum@@ or site, T and N clinical stages and P@@ S@@ WHO@@ ) *@@ *@@ L@@ og@@ ran@@ k test *@@ *@@ * Chi@@ -@@ square test
Sol@@ vent vial@@ : ethan@@ ol 95% water for injections.
The solvent for Docetaxel Winthrop is a 13@@ % w@@ / w solution of ethan@@ ol 95% in water for injections.
5@@ 6, 9@@ 5, per@@ -@@ protoc@@ ol analys@@ is) for the initial 6 months of follow-@@ up.
As with other seroton@@ in@@ ergic medicinal product, discontinuation symptoms may occur in the neon@@ ate after maternal duloxetine use near term.
General Disorders and Administration S@@ ite Con@@ di@@ tions
Consequently, caution is advised when D@@ UL@@ OX@@ E@@ TIN@@ E BO@@ E@@ H@@ RI@@ NG@@ ER ING@@ EL@@ HE@@ I@@ M is taken in combination with other centr@@ ally acting medicinal products and substances including alcohol and sed@@ ative medicinal products (e. g. benzodiazep@@ ines, morph@@ in@@ omime@@ tics, antipsycho@@ tics, phen@@ ob@@ arbit@@ al, sed@@ ative anti@@ hist@@ amin@@ es).
The following undesirable effects had a rate greater than placebo and have been reported among 15@@ 43 patients administered Dynastat 20 or 40 mg as a single or multiple dose (up to 80 mg/ day) in 12 placebo controlled studies, including d@@ ent@@ al, gy@@ na@@ ec@@ olog@@ ic, orthopaedic surgery or coronary artery by@@ pass graft surgery as well as pre-@@ operative administration in dental and orthopaedic surg@@ eri@@ es.
30 4.4 Special warnings and precautions for use
CON@@ DI@@ TIONS OF THE MARKETING AUTHORISATION
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
You will not be given Dynastat in the last three months of pregnancy.
No accumulation of epoetin del@@ ta was observed after repeated intravenous administration three times week@@ ly.
An@@ aemia in epo@@ et@@ in-@@ resistant or hypo@@ respon@@ sive patients with failure to respond to 20@@ ,000 IU/ week lp
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
Concomitant administration of memantine with the anti@@ spas@@ modi@@ c agents, d@@ ant@@ rol@@ ene or bac@@ lo@@ f@@ en, can modi@@ fy their effects and a dose adjustment may be necessary. • Concomitant use of memantine and am@@ ant@@ adine should be avo@@ ide@@ d, ow@@ ing to the risk of pharmac@@ otoxic psych@@ osis.
A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer's disease (MM@@ SE total scores at baseline of 10 to 2@@ 2) included 40@@ 3 patients.
No data on the use of memantine in patients with severe hepatic impairment are available.
You should inform your doctor if you have recently changed or intend to change your diet substantially (e. g. from normal diet to strict veget@@ arian di@@ et@@ ) or if you are suffering from states of renal tub@@ ul@@ ary acidosis (R@@ TA@@ , an excess of acid@@ -@@ form@@ ing substances in the blood due to renal dysfunction (@@ poor kidney function@@ )) or severe infections of the urinary tract (@@ structure that carries ur@@ ine@@ ), as your doctor may need to adjust the dose of your medicine.
- if you have recently experienced a myocardial infarc@@ tion (@@ heart attack@@ ), or if you are suffering
F@@ ru@@ c@@ tose Mann@@ itol Polysorbate 80 T@@ art@@ ar@@ ic acid Sodium hydrox@@ ide (for p@@ H-@@ adjustment) Hydro@@ chlor@@ ic acid (for p@@ H-@@ adjustment)
The reconstituted solution should be clear and free from visible particul@@ ates.
Ne@@ op@@ las@@ ms ben@@ ign@@ , malignant and un@@ specified (including cy@@ sts and poly@@ p@@ s)
T@@ oler@@ ance and physical and/ or psychological depend@@ ence may develop upon repeated administration of opi@@ oid@@ s such as fent@@ an@@ yl@@ .
Diffe@@ rences in exposure with Effentora were observed in a clinical study with patients with grade 1 mu@@ co@@ si@@ tis.
The main pharmacokinetic parameters are shown in the following table.
The incidence of hypoglycaemia in the sitagliptin group (@@ 4.@@ 9%) was significantly lower than that in the g@@ lip@@ iz@@ ide group (3@@ 2.@@ 0@@ %).
need to stop taking E@@ ffici@@ b for a couple of days before and after the procedure
Pharmac@@ okine@@ tics of pr@@ as@@ ugrel and its inhibition of platelet aggreg@@ ation were similar in subjects with mild to moderate hepatic impairment compared to healthy subjects.
This medicinal product has been authorised under “ Ex@@ cep@@ tional Circ@@ um@@ st@@ anc@@ es@@ ”.
Studies with eme@@ da@@ st@@ ine have not shown effects on adren@@ erg@@ ic, dop@@ amin@@ erg@@ ic, and serotonin receptors.
6.@@ 6 Instructions for use and hand@@ ling, and disposal
* The confidence intervals were calculated with no adjustment for age category (< 55 years, ≥ 55 years) and investig@@ ator group, which were included in the primary analysis of od@@ ds ratios and log@@ istic mod@@ els. † One patient in the A@@ pre@@ pit@@ ant Reg@@ im@@ en only had data in the acute phase and was excluded from the overall and delayed phase analys@@ es.
EMEND 1@@ 25 mg hard capsule EMEND 80 mg hard capsules A@@ pre@@ pit@@ ant
The interaction with mid@@ azol@@ am lac@@ ks clinical relevance but is indic@@ ative of a slight CYP3A4 inhibition by dar@@ ifen@@ ac@@ in.
Marketing Authorisation Holder Novartis Euro@@ ph@@ arm Limited W@@ im@@ ble@@ hur@@ st Road H@@ or@@ sha@@ m West Sus@@ sex@@ , R@@ H@@ 12 5@@ AB United Kingdom
What Emselex can be used for Emselex belongs to a class of medicines which rel@@ ax the muscles of the blad@@ der.
Such exacerbations have been seen following discontinuation of emtricit@@ abine treatment in HBV infected patients without concomitant HIV infection and have been detected primarily by serum alan@@ ine aminotransferase (AL@@ T) elevations in addition to re-@@ emergence of HBV DNA@@ .
Although the mean Cmax and Cmin were approximately 20% higher and mean AUC was 16% higher in fem@@ ales compared to mal@@ es, this difference was not considered clinically signific@@ ant.
Dose or dose interval adjustment is required in all patients with creatinine clearance < 50 ml/ min (see section 4.4).
E@@ arly symptoms (@@ symptomatic hyper@@ lactat@@ aem@@ ia) include ben@@ ign diges@@ tive symptoms (@@ nausea, vomiting and abdominal pain@@ ), non-@@ specific mala@@ ise, loss of appetite, weight loss, respiratory symptoms (@@ rapid and/ or deep breath@@ ing) or neurological symptoms (including motor weakness@@ ).
Rare cases of pancyt@@ openia and very rare cases of aplastic anaemia, some with fatal outcom@@ e, have been reported in patients treated with Enbrel@@ .
The efficacy of Enbrel was assessed in a randomised, double-@@ blin@@ d, placebo-controlled study.
Radi@@ ographic changes were assessed in the psoriatic arthritis study.
In general, the adverse events in paediatric patients with juvenile idi@@ opathic arthritis were similar in frequency and type to those seen in adult patients.
68 TNF and lymph@@ otox@@ in exist predominantly as hom@@ o@@ trim@@ ers, with their biological activity dependent on cross-@@ lin@@ king of cell surface TN@@ FR@@ s.
Meth@@ otrex@@ ate doses were escal@@ ated from 7.5 mg/ week to a maximum of 20 mg/ week over the first 8 weeks of the trial and continued for up to 24 months.
At 24 weeks, 56% of patients in the Enbrel@@ -treated group had achieved the P@@ AS@@ I 75 compared to 5% of placebo-treated patients.
With twice weekly doses, it is anticipated that steady-@@ state concentrations are approximately twice as high as those observed after single doses.
In some cases, particular fungal and other opportun@@ istic infections have not been recogn@@ ised, resulting in delay of appropriate treatment and sometimes death.
Infections (including upper respiratory tract infections, bronchitis, c@@ ys@@ ti@@ tis, skin infection@@ s)@@ * Uncommon:
Among rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and pla@@ que psoriasis patients in placebo-@@ controlled, activ@@ e-@@ controlled, and open-label trials of Enbrel@@ , serious adverse events reported included malignancies (see below@@ ), asth@@ ma, infections (see below@@ ), heart failure, myocardial infarc@@ tion, myocardial ischaem@@ ia, chest pain, syn@@ cop@@ e, cere@@ bral ischaem@@ ia, hypertension, hypoten@@ sion, chol@@ ec@@ ys@@ ti@@ tis, pancre@@ atitis, gastrointestinal haemorrhage, bur@@ si@@ tis, confusion, depression, dysp@@ noea, abnormal heal@@ ing, renal insuffici@@ ency, kidney calcul@@ us, deep vein thromb@@ osis, pulmonary embol@@ ism, membran@@ ous glomer@@ ul@@ one@@ ph@@ ro@@ path@@ y, poly@@ my@@ osi@@ tis, thromb@@ oph@@ leb@@ itis, liver damage, leuc@@ openia, pares@@ is, pares@@ thesia, ver@@ tigo, allergic al@@ ve@@ ol@@ itis, angi@@ oedema, scler@@ itis, bone fract@@ ure, lymp@@ ha@@ den@@ opathy, ulcerative col@@ itis, intestinal obstruc@@ tion, eosinophil@@ ia, haemat@@ uria, and s@@ ar@@ co@@ id@@ osis.
Enbrel treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondyli@@ tis, pla@@ que psoriasis or paediatric pla@@ que psori@@ as@@ is.
In a fourth study, the safety and efficacy of 50 mg Enbrel (@@ two 25 mg S@@ C injection@@ s) administered once weekly vs 25 mg Enbrel administered twice weekly were evaluated in a double-@@ blin@@ d, placebo-controlled study of 35@@ 6 patients with active ankylosing spondyli@@ tis.
Please read the instructions carefully and follow them step by step.
Tell you doctor if you are exposed to chicken@@ pox when using Enbrel@@ .
Me@@ als with a high fat content reduce Cmax by 8@@ 5% and AUC by 70@@ %.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
The study measured how long it took the children to develop an AID@@ S@@ -related ill@@ ness.
What is the risk associated with Epi@@ vir@@ ?
Since lamivudine is di@@ alys@@ able, continuous haemodialysis could be used in the treatment of over@@ dos@@ age, although this has not been studied.
For more information on bio@@ similar medicines, see the question@@ -and-@@ answer document here.
In patients with chronic renal failure the medicinal product has to be administered intraven@@ ously (see section 4.4).
In controlled clinical studies, use of E@@ poetin alfa and other erythropoies@@ is-@@ stimulating agents (E@@ SA@@ s) have sho@@ wn@@ :
An@@ aemia symptoms and sequ@@ el@@ ae may vary with age, gender, and overall burden of diseas@@ e; a physici@@ an@@ ´s evaluation of the individual patient@@ ´s clinical course and condition is necessary.
Adult patients with renal insufficiency not yet undergoing di@@ alys@@ is:
If anti-@@ erythropo@@ i@@ et@@ in, anti@@ bod@@ y-@@ mediated PRCA is suspected, therapy with E@@ poetin alfa HEXAL should be discontinued immediately.
H@@ b between 10 and 12 g/ dl (@@ 6.2 - 7.5 mmol/ l@@ ).
These increases in blood pressure can be treated with medicinal products.
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron defici@@ ent.
H@@ b 10 - 13 g/ d@@ l) who do not have an aut@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 18@@ 00 ml.
An@@ aemia symptoms and sequ@@ el@@ ae may vary with age, gender, and overall burden of diseas@@ e; a physici@@ an@@ ´s evaluation of the individual patient@@ ´s clinical course and condition is necessary.
It may be necessary to add or increase antihypertensive treatment.
- Oc@@ clusion in the connection between artery and vein (@@ sh@@ unt thromb@@ osis) may occur especially if
It must not be mixed with other intraven@@ ously applied medicinal products.
E@@ u@@ cre@@ as 50 mg/@@ 8@@ 50 mg film-coated tablets v@@ ild@@ aglip@@ tin@@ /@@ metformin hydrochloride
E@@ VI@@ ST@@ A should not be used in patients with hepatic impairment (see section 4.3).
Blood and lymph@@ atic system disorders Very ra@@ re: thrombocytopenia Gastrointestinal disorders Very ra@@ re:
The effect of bodyweight on active substance exposure suggests special attention to patients with very low body weight during up@@ -@@ titration (see section 4.4).
Common side effects (@@ affects 1 to 10 patients in 100@@ ) are: heart@@ bur@@ n, stomach pain, headache, agitation, confusion, weakness, fatigue, sweating, a general feeling of being un@@ well, weight loss and tre@@ mb@@ ling.
In patients with mild to moderate hepatic impairment without cholest@@ asis, the maximum recommended dose is 80 mg vals@@ art@@ an.
SPECIAL W@@ AR@@ N@@ ING T@@ HAT THE MEDICINAL PRODUCT MU@@ ST B@@ E ST@@ O@@ RE@@ D O@@ U@@ T OF THE REACH AND SI@@ G@@ H@@ T OF C@@ HI@@ LD@@ RE@@ N
Product information Phys@@ ician information about Ex@@ j@@ ade (@@ bro@@ ch@@ ure and p@@ ock@@ et car@@ d) Patient information pack
Doses of vitamin C up to 200 mg per day have not been associated with adverse consequences.
- change in the results of liver tests (@@ increase in the blood levels of enzymes produced by
Hypo@@ glycaemia can generally be corrected by immediate carbohydrate in@@ take.
ed ris ho St@@ ore your insulin inhal@@ er in a dry place at room
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
14 attributed to the formation of Ig@@ G antibodies and/ or comple@@ ment activ@@ ation.
The duration of treatment is adjusted depending on the patient 's uric@@ aemia (blood levels of uric acid@@ ) and the doctor@@ 's judg@@ ment.
Adverse reactions reported in a clinical trial following primary vaccination with Fendrix and considered as being related or possibly related to vaccination have been categor@@ ised by frequ@@ ency.
Monitoring of plasma Z@@ n@@ 2@@ + concentr@@ ation, and supplement@@ ation in case of a defici@@ ency, is recommended.
High density polyethylene (HDPE) bottles with child resistant closure (@@ poly@@ propyl@@ en@@ e).
It should be no@@ ted, however, that pregnancy itself also carries an increased risk of thromb@@ osis. • Fer@@ ta@@ vi@@ d may contain traces of stre@@ p@@ tom@@ ycin and/ or ne@@ omyc@@ in.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Marketing Authorisation Holder S@@ P Europe, Rue de Stal@@ le 7@@ 3, B@@ -1@@ 180 B@@ ru@@ x@@ ell@@ es, Belgi@@ um.
Like all medicines, Fer@@ ta@@ vi@@ d can cause side effects, although not every@@ body gets them.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Once the rubber in@@ lay of a cartridge is pi@@ erc@@ ed by a need@@ le, the product may be stored for a maximum of 28 days.
Filgrastim HEXAL contains the active substance filgrastim@@ .
Chem@@ ical and physical in-@@ use st@@ ability of the diluted solution for infusion has been demonstrated for 24 hours at 2@@ °C to 8@@ °C.
Some cases of splen@@ ic rup@@ ture were fatal.
Among these, two cases of platelets < 50 x 109/ l were reported and attributed to the leuk@@ ap@@ he@@ res@@ is procedure.
(N = 5@@ 6) Median time to regression of symptoms, by patient (@@ hour@@ s) All episodes
At@@ tain@@ ment of pro@@ state specific anti@@ gen (P@@ SA@@ ) reduction T@@ um@@ our size was not measured directly during the clinical trial programme, but there was an in@@ direct beneficial tumour response as shown by a 95% reduction after 12 months in median P@@ SA for de@@ g@@ are@@ li@@ x.
If you have any further questions on the use of this medicine, ask your doctor.
K@@ r@@ ó@@ lo@@ we@@ j Mar@@ y@@ si@@ e@@ ń ki 11 m.
- congenital ag@@ am@@ mag@@ lob@@ ulin@@ aemia and hypo@@ gam@@ mag@@ lob@@ ulin@@ aemia
The following dosage regim@@ ens are given as a guidel@@ ine.
Re@@ plac@@ ement therapy in primary immunodeficiency syndro@@ mes
Human normal immunoglobulin contains mainly immunoglobulin G (I@@ g@@ G@@ ) with a broad spectrum of antibodies against infectious agents.
The solution should be clear or slightly op@@ al@@ es@@ cent@@ .
However, in a pandemic situ@@ ation, it may be appropriate to give the vaccine, provided that facilities for resus@@ cit@@ ation are immediately available in case of need.
Because salmon calcitonin has been in use for some time, the company presented data to show that
6 The pivotal study included 16@@ 37 postmenopausal women (mean age 69@@ .@@ 5 year@@ s).
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
19 Some patients get dizz@@ y or get a fast heartbe@@ at after the first few doses.
Please speak to your doctor about this before you go home after being injected with Fos@@ can@@ .
7 tablets 14 tablets 28 tablets 30 tablets 56 tablets 60 tablets 90 tablets 1@@ 12 tablets 180 tablets 3@@ 36 tablets
When looking at two of the studies together, where GANFORT was compared with its components given as separate drops (@@ 1,0@@ 61 patient@@ s), and at patients whose pressure was not controlled with eye drops containing pro@@ stag@@ land@@ ins only (@@ about a third of them@@ ), the medicine was more effective than b@@ im@@ at@@ oprost on its o@@ wn.
Therefore, GANFORT should be used with caution in patients with known risk factors for macular oedema (e. g. ap@@ ha@@ k@@ ic patients, pseud@@ opha@@ k@@ ic patients with a tor@@ n po@@ ster@@ ior l@@ ens capsu@@ le@@ ).
25 Latvija All@@ erg@@ an Ltd 1@@ st F@@ lo@@ or Mar@@ low International The Park@@ way Mar@@ low Buc@@ ks, SL@@ 7 1@@ Y@@ L-@@ UK Li@@ el@@ b@@ rit@@ ā ni@@ ja Tel: + 44 (0) 16@@ 28 49@@ 4@@ 026 E-mail: uk@@ _@@ med@@ info@@@ allerg@@ an. com
When the injection is completed and the plunger is fully depres@@ sed, the plunger will eng@@ age the activation c@@ lip@@ s.
36 PAR@@ TIC@@ UL@@ ARS TO AP@@ PE@@ AR ON THE O@@ UTE@@ R PAC@@ K@@ AG@@ ING O@@ UTE@@ R CAR@@ T@@ ON TE@@ X@@ T G@@ ard@@ as@@ il, suspension for injection – pre-filled sy@@ r ing@@ e with 1 need@@ le, p ack of 1, 10, 20
OTHER SPECIAL W@@ AR@@ N@@ ING@@ (S@@ ), IF NE@@ CE@@ S@@ SAR@@ Y
Subst@@ anc@@ e-@@ specific side effects:
Four hours after oral administration of 20 mg/ kg body weight 5-@@ AL@@ A H@@ Cl@@ , the maximum P@@ P@@ IX plasma level is reach@@ ed.
me@@ da@@ c G@@ es@@ ell@@ sc@@ ha@@ ft f@@ ü@@ r k@@ lin@@ is@@ che S@@ pe@@ zi@@ al@@ pr@@ ä@@ par@@ ate mb@@ H The@@ ater@@ straße 6 D@@ -2@@ 28@@ 80 We@@ del Germany
I@@ mat@@ inib adverse events, i. e. hepat@@ otoxic@@ ity, myelo@@ suppression or others, may increase and it has been reported that concomitant use with L-@@ as@@ par@@ ag@@ inase could be associated with increased hepat@@ otoxicity (see section 4.8).
Ch@@ ec@@ k whether cyt@@ openia is related to leukaemia (@@ marrow aspir@@ ate or bi@@ op@@ sy@@ ).
Treatment with Glivec may be interrupted or the dose may be reduced, as
This time@@ -to-@@ event endpoint is strong@@ ly affected by the high cros@@ s@@ over rate from IF@@ N@@ +@@ A@@ ra@@ -@@ C to G@@ liv@@ ec@@ .
Dis@@ eas@@ e-@@ free survival (D@@ F@@ S) and overall survival (@@ OS@@ ) constantly exceeded 1 year and were su@@ peri@@ or to historical control (D@@ F@@ S p < 0.00@@ 1@@ ; O@@ S p < 0.@@ 000@@ 1) in two studies (A@@ J@@ P@@ 0@@ 1 and AU@@ S@@ 0@@ 1).
The more frequent adverse reactions included gastrointestinal haemorrhag@@ es, conjunctivi@@ tis and elev@@ ation of transamin@@ ases or bilirub@@ in.
For the patients treated at 600 mg, the current estimates for median progres@@ sion@@ -f@@ re@@ e-@@ survival and overall survival were 2@@ 2.@@ 9 and 4@@ 2.5 months, respectively.
These events can usually be managed with either a reduction of the dose or an interruption of treatment with G@@ liv@@ ec@@ , but can in rare cases lead to permanent discontinuation of treatment.
The first 77 patients were started at 400 mg, the protoc@@ ol was subsequently amended to allow higher dosing and the remaining 15@@ 8 patients were started at 600 mg.
There was no change in the k@@ ine@@ tics of im@@ atinib on repeated dos@@ ing, and accumulation was 1.@@ 5@@ – 2.@@ 5-fold at steady state when dos@@ ed once daily.
Although the results of pharmacokinetic analysis showed that there is considerable inter@@ -@@ subject vari@@ ation, the mean exposure to im@@ atinib did not increase in patients with varying degrees of liver dysfunction as compared to patients with normal liver function (see sections 4.@@ 2, 4.4 and 4.8).
These white cells usually help the body to fight infection.
- cardiac failure or history of cardiac failure (N@@ Y@@ H@@ A stages I to IV@@ )
However, this did not lead to an increase in mortality in this study.
If any patient develops symptoms suggesting hepatic dysfunction, which may include un@@ expl@@ ained nausea, vomiting, abdominal pain, fatigue, anorex@@ ia and/ or dark ur@@ ine, liver enzymes should be check@@ ed.
Hypo@@ glycaemia As a consequence of increased insulin sensitiv@@ ity, patients receiving pioglitazone in du@@ al or tri@@ ple oral therapy with a sulphonylurea or in du@@ al therapy with insulin may be at risk for dose-@@ related hypoglycaem@@ ia, and a reduction in the dose of the sulphonylurea or insulin may be necessary.
The other ingredients are lact@@ ose monohydrate, hy@@ pro@@ los@@ e, c@@ arm@@ ell@@ ose calcium and magnes@@ ium stear@@ ate.
What Glustin looks like and contents of the pack
Treatment is continued until adequate follic@@ ular development has been achieved (as assessed by monitoring of serum oestrogen concentrations and/ or ultras@@ ound examin@@ ation), with the dose adjusted according to the patient's response, to usually not higher than 450 IU daily.
It should be noted however, that pregnancy itself also carries an increased risk of thrombo@@ -@@ embolic events.
When an optimal response is ob@@ tain@@ ed, a single injection of 5 000 IU@@ , up to 10 000 IU h@@ C@@ G should be administered 24-@@ 48 hours after the last GONAL-f injection.
Treatment should be tail@@ o@@ red to the individual patient's response as assessed by measuring follic@@ le size by ultras@@ ound and oestrogen response.
The steady state volume of distribution and total clearance are 10 l and 0.6 l/ h, respectively.
EXP Shelf-life after first us@@ e:
If you have period@@ s, the treatment should start within the first 7 days of the menstrual cycle@@ .
The effects of an overdose of GONAL-f are unknown, nevertheless one could expect ovarian hyperstimulation syndrome to occur, which is further described in section 4.
24@@ 4 Eesti Österreich Merck Ser@@ on@@ o E@@ sin@@ da@@ ja C/ o A@@ res Tr@@ ading SA Baltic States Z@@ amen@@ ho@@ f@@ o 11-@@ 3, L@@ T-@@ 44@@ 28@@ 7 Ka@@ un@@ as, Le@@ ed@@ u Tel: +370 37@@ 3@@ 20@@ 60@@ 3
If you have not responded to treatment after this period, your treatment may carry on for at least 18 months.
Wh@@ il@@ st keeping the injection button pressed down, take the needle out of the skin.
After the addition of the emulsion to the suspen@@ sion, the mixture should be well sha@@ k@@ en.
SPECIAL W@@ AR@@ N@@ ING T@@ HAT THE MEDICINAL PRODUCT MU@@ ST B@@ E ST@@ O@@ RE@@ D O@@ U@@ T OF THE REACH AND SI@@ G@@ H@@ T OF C@@ HI@@ LD@@ RE@@ N
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
What HB@@ VA@@ X@@ PR@@ O 5 micrograms/ 0.5 ml looks like and contents of the pack
The analysis of the 13@@ C@@ /1@@ 2@@ C-@@ ratio in carbon dioxide of breath is an integrated part of the diagnostic test Helicobacter T@@ est IN@@ FA@@ I.
For introduction of the carbon dioxide into the analys@@ er many sample in@@ let systems are available.
Concomitant administration of 10 mg adefovir dipivox@@ il and 100 mg lamivudine did not alter the pharmacokinetic profile of either medicinal product.
In several clinical studies (H@@ Be@@ A@@ g posi@@ tive, HBe@@ A@@ g neg@@ ative, pre- and post-@@ liver transplantation with lamivud@@ ine-@@ resistant HBV and lamivud@@ ine-@@ resistant HBV co-infected with HIV patient@@ s), genoty@@ pic analys@@ es were conducted on HBV isolates from 37@@ 9 of a total of 6@@ 29 patients, treated with adefovir dipivox@@ il for 48 weeks.
26@@ 6@@ ±@@ 5@@ 5.@@ 7 35@@ 6@@ ±@@ 8@@ 5.@@ 6 14@@ 8@@ ±@@ 39@@ .@@ 3
When H@@ erc@@ ep@@ tin was used in combination with an@@ astro@@ zo@@ le, the median progres@@ sion@@ -free survival was 4.@@ 8 months, compared with 2.@@ 4 months in the patients taking an@@ astro@@ z@@ ole on its o@@ wn.
The extrac@@ ellular dom@@ ain of the receptor (E@@ C@@ D, p@@ 10@@ 5) can be sh@@ ed into the blood stream and measured in serum sampl@@ es.
I@@ HC@@ 3@@ + patient subset 2.
33 We do not know whether H@@ erc@@ ep@@ tin could affect your ability to drive a car or operate machin@@ er@@ y.
Not all packs may be marketed.
You should see a drop of insulin at the tip of the needle.
Insulin requirements may be increased during illness or emotional disturb@@ ances.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypo@@ glyc@@ em@@ ics, sal@@ ic@@ yl@@ ates (for example, acetylsalicylic acid@@ ), sulph@@ a antibiotics, certain anti@@ depres@@ sants (@@ monoamine oxidase inhibitor@@ s), certain angiotensin converting enzyme inhibitors (@@ cap@@ top@@ r@@ il, en@@ al@@ ap@@ ril@@ ), angiotensin II receptor block@@ ers, beta-@@ block@@ ers, oc@@ tre@@ otide or alcohol@@ .
In the figure below the pharmac@@ odynam@@ ics of Humalog Mix25 and BASAL are ill@@ u@@ str@@ ated.
Con@@ tain@@ s pro@@ t@@ amine sulph@@ ate, glycerol, zinc oxide, di@@ basic sodium phosphate 7 H@@ 20 with m-@@ cre@@ so@@ l and phen@@ ol as preserv@@ atives in water for injections.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
2@@ 39 • A few people who have had hypoglycaemia after switching from animal insulin to human insulin have reported that the early warning symptoms were less obvious or differen@@ t.
Some people get redness, swelling or itching around the area of the insulin injection.
Marketing Authorisation Holder and Manufacturer Humalog Mix25 100 U@@ /@@ ml Kwik@@ P@@ en, suspension for injection is made b@@ y: • Lilly France S.@@ A@@ .@@ S@@ ., Rue du Col@@ on@@ el L@@ ill@@ y, 67@@ 6@@ 40 F@@ eg@@ er@@ she@@ im@@ , France, • Lilly Pharma Fer@@ tig@@ ung un@@ d D@@ ist@@ rib@@ ution GmbH & Co@@ .
After treatment with Hum@@ ir@@ a, a rapid decrease in levels of acute phase react@@ ants of inflammation (C@@ -@@ reac@@ tive protein (C@@ R@@ P) and erythro@@ cy@@ te se@@ di@@ mentation rate (E@@ S@@ R@@ )) and serum cyto@@ k@@ ines (I@@ L-@@ 6) was observed compared to baseline in patients with rheumatoid arthri@@ tis.
In the open-label lead in phase (O@@ L LI@@ ) patients were str@@ ati@@ fied into two groups, MT@@ X (@@ methotrex@@ ate@@ )@@ -treated or non- MT@@ X@@ - treated.
Mann@@ itol C@@ it@@ ric acid mono@@ hydrate Sodium cit@@ rate Sodium dihydrogen phosphate di@@ hydrate Dis@@ odium phosphate di@@ hydrate Sodium chloride Polysorbate 80 Sodium hydrox@@ ide W@@ ater for injections.
No studies have been conducted that include patients with a history of malign@@ ancy or in whom treatment with Humira is continued following development of malignanc@@ y.
Two patients out of 3@@ ,@@ 4@@ 41 treated with Humira in all rheumatoid arthritis and psoriatic arthritis studies developed clinical signs suggestive of new-@@ onset l@@ up@@ us@@ -like syndrome.
ACR responses were maintained in the open-label extension study for up to 13@@ 6 weeks.
Patients who maintained ≥ P@@ AS@@ I 75 response at Week 33 and were origin@@ ally randomised to active therapy in Peri@@ od A, were re-@@ randomised in period C to receive 40 mg Humira every other week or placebo for an additional 19 weeks.
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dys@@ cr@@ as@@ i@@ as (e. g. persistent fever, bru@@ is@@ ing, bleeding, p@@ all@@ or) while on Hum@@ ir@@ a.
Injection site reactions generally did not necessitate discontinuation of the medicinal product.
In patients not given concomitant methotrex@@ ate, the incidence was 1@@ 6/ 18@@ 5 (@@ 8.@@ 6@@ %), compared to 1/ 19 (5.@@ 3%) when adalimumab was used as add-on to methotrexate.
111 As per the CHMP guid@@ eline on the Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (P@@ SU@@ R)
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Tel: + 4@@ 21 (0)@@ 2 48 26 11 11 rec@@ ep@@ ci@@ a. sk@@ @gsk@@ . com
The active substances are sp@@ lit In@@ flu@@ enza virus@@ *, inactiv@@ ated, containing antigens equivalent to the following strain@@ s:
Renal impairment No dosage adjustment of Imprida is required for patients with mild to moderate renal impairment (@@ GF@@ R > 30 ml/ min@@ / 1.@@ 73 m@@ 2).
Ex@@ cep@@ tional cases of extr@@ ap@@ yr@@ am@@ idal syndrome have been reported.
OTHER SPECIAL W@@ AR@@ N@@ ING@@ (S@@ ), IF NE@@ CE@@ S@@ SAR@@ Y
An appropriate antihypertensive medication must usually replace Imprida before starting a pregnancy.
If you@@ /@@ your child take INC@@ RE@@ L@@ EX@@ , you@@ /@@ your child should avoid particip@@ ating in high risk activities (such as vi@@ go@@ rous physical activ@@ ity) within 2 to 3 hours after INC@@ RELE@@ X injection, especially at the beginning of INC@@ RELE@@ X treatment.
Animal studies have been conducted that cannot rule out effects of anti-@@ di@@ bo@@ ter@@ min alfa antibodies on embry@@ o-@@ foetal development (see section 5.3).
In@@ hal@@ ed nit@@ ric oxide has been found to approximately double bleeding time in a limited study in rab@@ b@@ its and humans.
Studies in animals revealed no teratogenic effect but foet@@ otoxicity in presence of maternal toxicity (see Section 5.3).
OTHER SPECIAL W@@ AR@@ N@@ ING@@ (S@@ ), IF NE@@ CE@@ S@@ SAR@@ Y
SPECIAL W@@ AR@@ N@@ ING T@@ HAT THE MEDICINAL PRODUCT MU@@ ST B@@ E ST@@ O@@ RE@@ D O@@ U@@ T OF THE REACH AND SI@@ G@@ H@@ T OF C@@ HI@@ LD@@ RE@@ N
Nov@@ o Nor@@ dis@@ k A/ S Nov@@ o All@@ é DK-2@@ 8@@ 80 B@@ ag@@ s@@ v@@ æ@@ r@@ d Denmark
Your ability to concentrate or to react will be less during a hypo@@ .
The amount or tim@@ ing of insulin, food or exercise may need to be adjust@@ ed.
Tell your rel@@ atives, fri@@ ends and close colleagu@@ es that if you pass out (@@ become un@@ consci@@ ous@@ ), they mu@@ st@@ : turn you on your side and seek medical advice straight away.
Insulin Human Winthrop contains the active substance insulin human.
For the full list of all side effects reported with Insulin Human Winthro@@ p, see the Package Leafle@@ t.
Caution should be exercised when prescribing to pregnant women.
Insulin Human Winthrop Rapid is administered subcutane@@ ously.
Insulin Human Winthrop Rapid must only be used if the solution is clear, colour@@ less, with no solid particles vis@@ ible, and if it is of a water@@ -like consist@@ ency.
Ad@@ he@@ rence of the patient to the dosage and dietary regim@@ en, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaem@@ ia.
The pen in-@@ use or carried as a sp@@ are may be stored for a maximum of 4 weeks not above 25@@ °C away from direct heat or direct light.
